AbbVie Ups Ante In Biosimilar Battle
AbbVie is pressuring the U.S. Food and Drug Administration to demand exhaustive research before allowing biosimilars to be automatically substituted for brand-name biologics, a position that would hammer the budding biosimilar...To view the full article, register now.
Already a subscriber? Click here to view full article